2 results
Approved WMOCompleted
The objectives of this study are to compare the safety and efficacy of 2 annual cycles of intravenous (IV) alemtuzumab to 3-times weekly subcutaneous (SC) interferon beta 1a (Rebif*) in patients with active relapsing-remitting multiple sclerosis (…
Approved WMORecruiting
The VAT project is set out to prove that this approach is superior and that the Quality of Life of children with amblyopia might be significantly improved in comparison to occlusion therapy.